 

Active Ingredient: Amantadine hydrochloride 

 

Dosage Form; Route: Capsule; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover 

Strength: 100 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: Since amantadine is known to be excreted in human milk, FDA 
recommends that the study exclude lactating women. In addition, due to the potential risk 
to the embryo or fetus, the study should exclude pregnant women, and other female study 
subjects should be counseled to practice abstinence or an appropriate form of 
contraception. 

___________________________________________________________________________ 

2. Type of study: Fed 


Design: Single-dose, two-way crossover 

Strength: 100 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: Same as above 

___________________________________________________________________________ 

Analytes to measure (in appropriate biological fluid): Amantadine in plasma 

 

Bioequivalence based on (90% CI): Amantadine 

 

Waiver request of in vivo testing: Not applicable 

 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units of the test and reference products. 
Specifications will be determined upon review of the abbreviated new drug application (ANDA). 


